BioSpace News Archive

BioMed Diagnostics, a leader in microbiological testing and a DCN Dx brand, is pleased to announce their attendance at VMX 2024.

LadRx Corporation issued the below letter to shareholders providing a corporate update and anticipated milestones for 2024 regarding arimoclomol and LADR-7.

Halberd Corporation is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa,. Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors.

Establishment Labs Holdings Inc. today announced it has entered into a securities purchase agreement with select institutional accredited investors to purchase common shares of the Company, or pre-funded warrants in lieu thereof.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SLS009 (formerly GFH009), its novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML).

Recently, Medicilon appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit.

NeuroBo Pharmaceuticals, Inc. announced that on January 8, 2024 , it received formal notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq’s minimum bid price equirement.

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that, through a joint proposal with Northeastern University and The TIM Company, it has been awarded a new funded grant from the U.S. Food and Drug Administration (FDA).

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, will present today at the 42nd Annual J.P. Morgan Healthcare Conference at 10:30 am PT (1:30 pm ET), and a live webcast will be available at www.edgewisetx.com.

GBI BioManufacturing, formerly known as Goodwin Biotechnology, proudly announces the signing of its second Master Supply Agreement for commercializing a radioimmunoconjugate product.